Determination and Quantitation of Cytotoxic T Cell-Mediated Cell Death

Author(s):  
Han-Hsuan Fu ◽  
Harry Qui
Keyword(s):  
T Cell ◽  
2021 ◽  
pp. 2100005
Author(s):  
David J. Peeler ◽  
Albert Yen ◽  
Nicholas Luera ◽  
Patrick S. Stayton ◽  
Suzie H. Pun

Head & Neck ◽  
2020 ◽  
Vol 42 (11) ◽  
pp. 3226-3234
Author(s):  
Stefan Kraft ◽  
Shekhar K. Gadkaree ◽  
Daniel G. Deschler ◽  
Derrick T. Lin ◽  
Mai P. Hoang ◽  
...  

2015 ◽  
Vol 290 (11) ◽  
pp. 6868-6877 ◽  
Author(s):  
Elena Catalán ◽  
Paula Jaime-Sánchez ◽  
Nacho Aguiló ◽  
Markus M. Simon ◽  
Christopher J. Froelich ◽  
...  

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Zhenqing Wang ◽  
Liang Chen ◽  
Yiqun Ma ◽  
Xilei Li ◽  
Annan Hu ◽  
...  

AbstractThe clinical treatment of metastatic spinal tumor remains a huge challenge owing to the intrinsic limitations of the existing methods. Programmed cell death protein 1 (PD1)/programmed cell death ligand 1 (PD-L1) pathway blockade has been explored as a promising immunotherapeutic strategy; however, their inhibition has a low response rate, leading to the minimal cytotoxic T cell infiltration. To ameliorate the immunosuppressive microenvironment of intractable tumor and further boost the efficacy of immunotherapy, we report an all-round mesoporous nanocarrier composed of an upconverting nanoparticle core and a large-pore mesoporous silica shell (UCMS) that is simultaneously loaded with photosensitizer molecules, the IDO-derived peptide vaccine AL-9, and PD-L1 inhibitor. The IDO-derived peptide can be recognized by the dendritic cells and presented to CD8+ cytotoxic T cells, thereby enhancing the immune response and promoting the killing of the IDO-expressed tumor cells. Meanwhile, the near-infrared (NIR) activated photodynamic therapy (PDT) could induce immunogenic cell death (ICD), which promotes the effector T-cell infiltration. By combining the PDT-elicited ICD, peptide vaccine and immune checkpoint blockade, the designed UCMS@Pep-aPDL1 successfully potentiated local and systemic antitumor immunity and reduced the progression of metastatic foci, demonstrating a synergistic strategy for cancer immunotherapy.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 1267-1267
Author(s):  
J.F. de Vries ◽  
P.A. von dem Borne ◽  
M.H.M. Heemskerk ◽  
R. Willemze ◽  
J.H.F. Falkenburg ◽  
...  

Abstract Cytotoxic T lymphocytes (CTLs) mediate target cell death by different effector mechanisms. We investigated whether a correlation exists between the kinetics of CTL-induced killing of the target cell and the different apoptotic pathways executed by the CTL. Different CTL clones were isolated using from a patient with CML after receiving donor lymphocyte infusions from an HLA-identical donor. These CTL clones recognized minor antigens expressed on the EBV-LCL cells from the patient. Since these clones were not all equally effective in killing the same target cells, we hypothesized that these T cells may induce different apoptotic pathways. In order to study the different execution pathways in the target cell, we generated retroviral constructs encoding the anti-apoptotic genes FADD-DN and FLIP, both inhibiting death receptor-mediated killing, and the granzyme B (GrB)-inhibitor PI-9. Using a retroviral delivery system, these constructs were transduced to the EBV-LCL cells. The cells highly overexpressing the gene of interest were sorted based on coexpression of a reporter gene, which was confirmed by Western Blot analysis. Both the wildtype (EBV-WT) and the transduced EBV cells (EBV-FADD-DN, EBV-FLIP and EBV-PI-9) were used as targets and the different CTL clones as effectors (E:T ratio = 1:1) in a quantitative CFSE-based cytotoxicity assay using Flow-Count Fluorospheres. To analyze the mechanism of immediate cell death caused by rapidly killing CTL clones, EBV-WT cells were exposed for 2 hours (h) to these clones, resulting in 30% lysis. This lysis could neither be blocked by FADD-DN or FLIP, nor by PI-9. Furthermore, no inhibition was obtained using the general caspase-inhibitor z-VAD-FMK, indicating that the killing was caspase-independent. In agreement with this observation, specific triggering of the Fas receptor pathway by an agonistic Fas antibody (100 ng/ml) did not induce any apoptosis within 2 h. To study CTL-induced cell death after a longer period, we analyzed CTL clones with different rates of killing and measured cytotoxicity after 5 and 24 h. Rapidly killing clones induced 60–70% cell death of the EBV-WT within 5 h, whereas slowly killing CTL clones did not show cytotoxicity after 5 h, but induced 50–60% cell death of EBV-WT after 24 h of incubation. Inhibition of CTL-mediated cell death by overexpression of the different anti-apoptotic proteins was comparable for all types of clones, showing 10–35% inhibition by either FADD-DN or FLIP and 20–55% by PI-9, indicating that both pathways are involved. As control, Fas antibody-induced apoptosis was almost completely inhibited in EBV-FADD-DN and EBV-FLIP, demonstrating highly effective block of the Fas-receptor pathway by these constructs. These results indicate that despite different kinetics of killing, all T cell clones used both the death receptor pathway and GrB release to kill its targets. In conclusion: 1. Interference with the Fas receptor or the GrB effector pathway cannot prevent CTL-mediated target cell death within the first 2 h of exposure, indicating that this lysis is probably directly perforin-mediated. 2. Both slowly and rapidly killing CTL clones use various effector mechanisms to kill their target cells, including both the death receptor and GrB pathways. In case of slower mediated cell death, not the execution pathway induced by the CTL, but affinity between TCR and MHC/peptide complex and other effector/target interactions more likely determine the kinetics of CTL-mediated cell death.


Cancers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1181 ◽  
Author(s):  
Mikołaj Wołącewicz ◽  
Rafał Hrynkiewicz ◽  
Ewelina Grywalska ◽  
Tomasz Suchojad ◽  
Tomasz Leksowski ◽  
...  

Bladder cancer is one of the most significant genitourinary cancer, causing high morbidity and mortality in a great number of patients. Over the years, various treatment methods for this type of cancer have been developed. The most common is the highly efficient method using Bacillus Calmette-Guerin, giving a successful effect in a high percentage of patients. However, due to the genetic instability of bladder cancer, together with individual needs of patients, the search for different therapy methods is ongoing. Immune checkpoints are cell surface molecules influencing the immune response and decreasing the strength of the immune response. Among those checkpoints, the PD-1 (programmed cell death protein-1)/PD-L1 (programmed cell death protein ligand 1) inhibitors aim at blocking those molecules, which results in T cell activation, and in bladder cancer the use of Atezolizumab, Avelumab, Durvalumab, Nivolumab, and Pembrolizumab has been described. The inhibition of another pivotal immune checkpoint, CTLA-4 (cytotoxic T cell antigen), may result in the mobilization of the immune system against bladder cancer and, among anti-CTLA-4 antibodies, the use of Ipilimumab and Tremelimumab has been discussed. Moreover, several different approaches to successful bladder cancer treatment exists, such as the use of ganciclovir and mTOR (mammalian target of rapamycin) kinase inhibitors, IL-12 (interleukin-12) and COX-2 (cyclooxygenase-2). The use of gene therapies and the disruption of different signaling pathways are currently being investigated. Research suggests that the combination of several methods increases treatment efficiency and the positive outcome in individual.


2020 ◽  
Vol 8 (2) ◽  
pp. e001278
Author(s):  
Maysaloun Merhi ◽  
Afsheen Raza ◽  
Varghese Philipose Inchakalody ◽  
Kodappully S Siveen ◽  
Deepak Kumar ◽  
...  

Combined radioimmunotherapy is currently being investigated to treat patients with cancer. Anti-programmed cell death-1 (PD-1) immunotherapy offers the prospect of long-term disease control in solid tumors. Radiotherapy has the ability to promote immunogenic cell death leading to the release of tumor antigens, increasing infiltration and activation of T cells. New York esophageal squamous cell carcinoma-1 (NY-ESO-1) is a cancer–testis antigen expressed in 20% of advanced gastric cancers and known to induce humoral and cellular immune responses in patients with cancer. We report on the dynamic immune response to the NY-ESO-1 antigen and important immune-related biomarkers in a patient with metastatic gastric cancer treated with radiotherapy combined with anti-PD-1 pembrolizumab antibody.Our patient was an 81-year-old man diagnosed with locally advanced unresectable mismatch repair-deficient gastric cancer having progressed to a metastatic state under a second line of systemic treatment consisting of an anti-PD-1 pembrolizumab antibody. The patient was subsequently treated with local radiotherapy administered concomitantly with anti-PD-1, with a complete response on follow-up radiologic assessment. Disease control was sustained with no further therapy for a period of 12 months before relapse. We have identified an NY-ESO-1-specific interferon-γ (IFN-γ) secretion from the patients’ T cells that was significantly increased at response (****p˂0.0001). A novel promiscuous immunogenic NY-ESO-1 peptide P39 (P153–167) restricted to the four patient’s HLA-DQ and HLA-DP alleles was identified. Interestingly, this peptide contained the known NY-ESO-1-derived HLA-A2-02:01(P157–165) immunogenic epitope. We have also identified a CD107+ cytotoxic T cell subset within a specific CD8+/HLA-A2-NY-ESO-1 T cell population that was low at disease progression, markedly increased at disease resolution and significantly decreased again at disease re-progression. Finally, we identified two groups of cytokines/chemokines. Group 1 contains five cytokines (IFN-γ, tumor necrosis factor-α, interleukin-2 (IL-2), IL-5 and IL-6) that were present at disease progression, significantly downregulated at disease resolution and dramatically upregulated again at disease re-progression. Group 2 contains four biomarkers (perforin, soluble FAS, macrophage inflammatory protein-3α and C-X-C motif chemokine 11/Interferon–inducible T Cell Alpha Chemoattractant that were present at disease progression, significantly upregulated at disease resolution and dramatically downregulated again at disease re-progression. Combined radioimmunotherapy can enhance specific T cell responses to the NY-ESO-1 antigen that correlates with beneficial clinical outcome of the patient.


Sign in / Sign up

Export Citation Format

Share Document